SARS-CoV-2-Triggered Hemophagocytic Lymphohistiocytosis with Complications of Posterior Reversible Encephalopathy Syndrome.

IF 0.7 Q4 PEDIATRICS
Case Reports in Pediatrics Pub Date : 2024-07-30 eCollection Date: 2024-01-01 DOI:10.1155/2024/8829060
Ross M Perry, Scott D Casey, Alex Q Lee, Sylvia P Bowditch, Mary A Rasmussen, Viyeka Sethi, Arun R Panigrahi
{"title":"SARS-CoV-2-Triggered Hemophagocytic Lymphohistiocytosis with Complications of Posterior Reversible Encephalopathy Syndrome.","authors":"Ross M Perry, Scott D Casey, Alex Q Lee, Sylvia P Bowditch, Mary A Rasmussen, Viyeka Sethi, Arun R Panigrahi","doi":"10.1155/2024/8829060","DOIUrl":null,"url":null,"abstract":"<p><p>In this article, we describe a novel case of SARS-CoV-2-associated-hemophagocytic lymphohistiocytosis (HLH) complicated by posterior reversible encephalopathy syndrome (PRES). Initially diagnosed with multisystem inflammatory response in children (MIS-C), the patient received a large corticosteroid dose days before the onset of neurological symptoms. After developing PRES, the patient was treated with antihypertensives, antiepileptics, dexamethasone, and anakinra, leading to neurologic normalization. We propose that given the challenging diagnostic picture of PRES developing in patients with HLH or MIS-C, institutionalized standards for blood pressure management during corticosteroid induction may significantly improve outcomes in patients being treated for hyperinflammatory syndromes who develop neurological symptoms.</p>","PeriodicalId":9623,"journal":{"name":"Case Reports in Pediatrics","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11303060/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Pediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2024/8829060","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

In this article, we describe a novel case of SARS-CoV-2-associated-hemophagocytic lymphohistiocytosis (HLH) complicated by posterior reversible encephalopathy syndrome (PRES). Initially diagnosed with multisystem inflammatory response in children (MIS-C), the patient received a large corticosteroid dose days before the onset of neurological symptoms. After developing PRES, the patient was treated with antihypertensives, antiepileptics, dexamethasone, and anakinra, leading to neurologic normalization. We propose that given the challenging diagnostic picture of PRES developing in patients with HLH or MIS-C, institutionalized standards for blood pressure management during corticosteroid induction may significantly improve outcomes in patients being treated for hyperinflammatory syndromes who develop neurological symptoms.

SARS-CoV-2引发的嗜血细胞淋巴组织细胞增多症并发后可逆性脑病综合征
本文描述了一例新型 SARS-CoV-2 相关性嗜血细胞淋巴组织细胞增多症(HLH)并发后可逆性脑病综合征(PRES)的病例。患者最初被诊断为儿童多系统炎症反应(MIS-C),在出现神经系统症状前几天接受了大剂量皮质类固醇治疗。在出现 PRES 后,患者接受了降压药、抗癫痫药、地塞米松和阿纳金雷的治疗,最终神经功能恢复正常。我们建议,鉴于 HLH 或 MIS-C 患者出现 PRES 的诊断情况极具挑战性,在皮质类固醇诱导期间对血压进行制度化管理可能会显著改善因高炎症综合征接受治疗并出现神经症状的患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
11.10%
发文量
48
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信